<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jesus Rojas Jaimes</style></author><author><style face="normal" font="default" size="100%">Juana E. Chavez-Flores</style></author><author><style face="normal" font="default" size="100%">Jenny Estela Villalobos</style></author><author><style face="normal" font="default" size="100%">Ashley Mantilla Aliaga</style></author><author><style face="normal" font="default" size="100%">Roxana Miranda Sanchez</style></author><author><style face="normal" font="default" size="100%">Zulema Suricachi Cerron</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Analgesic Effect of the Chloroformic Extract of Aniba canelilla “canelon” Bark in BALB/c Mice</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Analgesic</style></keyword><keyword><style  face="normal" font="default" size="100%">Aniba canelilla</style></keyword><keyword><style  face="normal" font="default" size="100%">Pain</style></keyword><keyword><style  face="normal" font="default" size="100%">Palliative</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2025</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">231-235</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background.&lt;/strong&gt; Some diseases can cause intense pain, where pharmacological treatment with opioid analgesics is necessary, as in cancer. Despite advances in cancer treatment, pain is still a common symptom. Treatment is usually based on the use of opioids, but there is still some rejection because of their adverse effects or because of the delay in access to them. To evaluate the analgesic effect of &lt;em&gt;Aniba canelilla&lt;/em&gt; &quot;canelon&quot; bark in mice to validate the above and consider it an alternative to existing palliative treatment in cancer patients. &lt;strong&gt;Methodology.&lt;/strong&gt; The analgesic effect was evaluated according to the method of Koster et al. using 50 BALB/c mice distributed in groups of 07 mice each. Comparison was made with the standards Tramadol 50 mg/kg and Paracetamol 500 mg/kg administered orally, and acetic acid 0.8% was used intraperitoneally as a pain inducer. &lt;strong&gt;Results.&lt;/strong&gt; The potent analgesic effect of the chloroformic extract of Aniba canelilla at 200mg/kg was observed, with an analgesic percentage of 98.87% with a mean number of writhes of 28.29 ± 5.44, being statistically significant to the other treatments (p&amp;lt;0.01). &lt;strong&gt;Conclusions &lt;/strong&gt;The analgesic effect of the chloroformic extract of &lt;em&gt;Aniba canelilla&lt;/em&gt; at 200mg/kg was determined.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">231</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Jesús Rojas Jaimes&lt;sup&gt;1&lt;/sup&gt;, Juana E. Chávez-Flores&lt;sup&gt;2&lt;/sup&gt;, Jenny Estela Villalobos&lt;sup&gt;2&lt;/sup&gt;, Ashley Mantilla Aliaga&lt;sup&gt;2&lt;/sup&gt;, Roxana Miranda Sanchez&lt;sup&gt;2&lt;/sup&gt;, Zulema Suricachi Cerrón&lt;sup&gt;2&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Escuela de Ciencias de la Salud, Universidad Privada del Norte, Lima-PERU.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Facultad de Farmacia y Bioquímica, Universidad Norbert Wiener, Lima, PERU.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hugo Jesús Justil-Guerrero</style></author><author><style face="normal" font="default" size="100%">Jorge Luis Arroyo-Acevedo</style></author><author><style face="normal" font="default" size="100%">Juan Pedro Rojas-Armas</style></author><author><style face="normal" font="default" size="100%">Miriam Palomino- Pacheco</style></author><author><style face="normal" font="default" size="100%">Carlos Orlando Garcia-Bustamante</style></author><author><style face="normal" font="default" size="100%">Edwin Cesar Cieza-Macedo</style></author><author><style face="normal" font="default" size="100%">Jessica Yolanda Huarcaya-Rojas</style></author><author><style face="normal" font="default" size="100%">Jaime David Torres-Lévano</style></author><author><style face="normal" font="default" size="100%">Julio Jose Pena-Galindo</style></author><author><style face="normal" font="default" size="100%">Esther Obdulia Franco-Soto</style></author><author><style face="normal" font="default" size="100%">Juana E. Chavez-Flores</style></author><author><style face="normal" font="default" size="100%">Robert Armando Cardenas-Orihuela</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antioxidant and Neuroprotective Effects of Chuquiraga spinosa Less. and Baccharis genistelloides (Pers.) Lam. in a Rat Model of Transient Cerebral Ischemia-reperfusion</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cerebral ischemia; neuroprotection; antioxidants; Chuquiraga spinosa Less.; Baccharis genistelloides (Pers.) Lam</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">September 2025</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">620-631</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Cerebral ischemia, a leading cause of disability and mortality, is strongly related to oxidative stress and inflammation, highlighting the need for neuroprotective antioxidant and cytokinemodulating agents. &lt;strong&gt;Objective: &lt;/strong&gt;To characterize the phytochemical profile and evaluate the antioxidant and neuroprotective effects of hydroalcoholic extracts of&lt;em&gt; Chuquiraga spinosa &lt;/em&gt;(ChS) and &lt;em&gt;Baccharis genistelloides&lt;/em&gt; (BaG), individually and in combination, in a rat model of cerebral ischemia–reperfusion. &lt;strong&gt;Methodology: &lt;/strong&gt;Phytochemical screening and GC-MS were performed with antioxidant assays (ABTS•⁺, DPPH•, FRAP). Neurological deficit was assessed (Bederson scale), while histopathology, oxidative stress markers (MDA, GSH, SOD, CAT, NOx), and cytokines (IL-6, TNF-α, IL-1β) were measured. Groups included Normal (no ischemia), Ischemia (oral placebo), Citicoline 300 mg/kg, ChS 500 mg/kg, BaG 500 mg/kg, and the oral combination ChS 500 + BaG 500 mg/kg, all administered for seven days prior to ischemia induction. &lt;strong&gt;Results: &lt;/strong&gt;ChS had higher total phenolic content than BaG (p = 0.0079). GC-MS identified 23 compounds in ChS and 17 in BaG. The combination displayed greater antioxidant activity than either extract. At 24 h, ChS 500 mg/Kg and the combination reduced severe neurological deficit to 17% (vs. 83% in ischemia). Histopathology revealed less neuronal damage with the combination, comparable to ChS 500 mg/Kg. All treatments decreased MDA levels; the combination also enhanced GSH and CAT and significantly reduced TNF-α and IL-1β. &lt;strong&gt;Conclusion:&lt;/strong&gt; ChS and BaG extracts exert neuroprotective effects against cerebral ischemia. Their combination shows synergistic antioxidant activity against free radicals and enhances the modulation of inflammatory cytokines, supporting a greater neuroprotective potential.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">620</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Hugo Jesús Justil-Guerrero&lt;sup&gt;1*&lt;/sup&gt;, Jorge Luis Arroyo-Acevedo&lt;sup&gt;1&lt;/sup&gt;, Juan Pedro Rojas-Armas&lt;sup&gt;1&lt;/sup&gt;, Miriam Palomino- Pacheco&lt;sup&gt;2&lt;/sup&gt;, Carlos Orlando García-Bustamante&lt;sup&gt;1&lt;/sup&gt;, Edwin César Cieza-Macedo&lt;sup&gt;1&lt;/sup&gt;, Jessica Yolanda Huarcaya-Rojas&lt;sup&gt;3&lt;/sup&gt;, Jaime David Torres-Lévano&lt;sup&gt;3&lt;/sup&gt;, Julio José Peña-Galindo&lt;sup&gt;3&lt;/sup&gt;, Esther Obdulia Franco-Soto&lt;sup&gt;3&lt;/sup&gt;, Juana E. Chávez-Flores&lt;sup&gt;4&lt;/sup&gt;, Robert Armando Cárdenas-Orihuela&lt;sup&gt;5&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Laboratory of Pharmacology, Faculty of Medicine, Universidad Nacional Mayor de San Marcos,Lima, PERÚ.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Laboratory of Biochemistry, Faculty of Medicine, Universidad Nacional Mayor de San Marcos, Lima, PERÚ.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Laboratory of Pharmacognosy, Faculty of Pharmacy and Biochemistry, Universidad Nacional San Luis Gonzaga, Ica, PERÚ.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Laboratory of Chemistry, Faculty of Pharmacy and Biochemistry, Universidad Científica del Sur, Lima, PERÚ.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Laboratory of Pharmacology, Academic Program of Pharmacy and Biochemistry, Universidad Norbert Wiener, Lima, PERÚ&lt;/p&gt;
</style></auth-address></record></records></xml>